ASCO 2025
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
68Ga-NY104 detected using PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with mccRCC.
Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
Updated phase 3 study assesses long-term outcomes of adjuvant pembrolizumab in patients with ccRCC at risk of recurrence.
Tumor microenvironment and circulating factors studied for potential links to treatment response in aRCC.
Interim SURE-02 study examines sacituzumab govitecan plus pembrolizumab in patients with MIBC unfit for chemotherapy.
Updated CREST trial explores sasanlimab plus BCG in BCG-naive, high-risk NMIBC, with new insights by disease stage and tumor.
ctDNA analysis from the NIAGARA trial offers new insights for patients with MIBC receiving perioperative durvalumab.
Enfortumab + pembrolizumab showed improved responses over chemo in untreated la/mUC, per updated EV-302 results.
Pathologic response and IHC post-treatment influx of CD8+CD39+ TILs are linked with prolonged DFS after neoadjuvant therapy.
Researchers evaluated SBRT plus short-term hormonal therapy in oligometastatic HSPC, examining the tolerability and efficacy.
A novel algorithm identifies patients with high-risk non-metastatic PCa who may benefit from second-generation ARPIs.
Nivolumab + ipilimumab provided a favorable landmark OS in cisplatin-ineligible patients with unresectable or metastatic UC.
The addition of ipi/nivo to LuPSMA improved PSA-PFS over 12 months in patients with mCRPC.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on ARANOTE, Metacure, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on KEYNOTE-564, NEOAVAX, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CREST, ENLIGHTED, and more.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.